Suven Life Sciences gets 3 patents in Canada, China, India

Tags: Companies
Pharmaceutical firm Suven Life has received three product patents in Canada, China and India for its new chemical entities for treatment of disorders associated with neurodegenerative diseases.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and these patents are valid through 2025, the company said in a filing to the BSE today.

Suven CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

These new chemical entities are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia, the filing said.

With these new patents, the company has a total of 14 granted patents from Canada, 12 from China and 17 from India.

Products out of these inventions may be out-licensed at various phases of clinical development, the company said.

EDITORIAL OF THE DAY

  • Annual reports make sense only if accountable governance is in place

    It’s a sign of a lack of imagination to expect an annual report by a party in power to pull out some impressive performance given the complex nature

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Amita Sharma

Political rhetoric makes for counter poetry

Poetic flourishes flavour politics. Ghalib and Hafez flowed profusely to ...

Zehra Naqvi

Watch your words, for they can kill

You must’ve heard the ph­rase ‘if looks could kill’. Ever ...

Dharmendra Khandal

Biodiversity day has come and gone. Yet again

Every year on May 22, world celebrates international biodiversity day. ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture